Session » (1913–1944) Miscellaneous Rheumatic & Inflammatory Diseases Poster III

Date: Tuesday, November 14, 2023

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2023

9:00AM-11:00AM: Abstract Number: 1920

A Phase Ib/II Randomized, Double-blind, Placebo-controlled Study of Novel anti-IL-17A Monoclonal Antibody JS005 in Patients with Moderate to Severe Psoriasis

9:00AM-11:00AM: Abstract Number: 1940

A Single-center, Observational, Retrospective, Case Control Study of Rituximab for the Treatment of Interstitial Pneumonia Associated with Autoimmune Features

9:00AM-11:00AM: Abstract Number: 1929

Anakinra Treatment in Idiopathic Recurrent Pericarditis: A Single-center Experience

9:00AM-11:00AM: Abstract Number: 1933

Analysis of IgG4-Related Disease in a Diverse Long Island Population: Insights from the Rheumatology Clinic

9:00AM-11:00AM: Abstract Number: 1931

Anti-Ku Antibodies: A Case Series

9:00AM-11:00AM: Abstract Number: 1919

Arthroplasty Outcomes in Immune Checkpoint Inhibitor-Treated Patients: A Single Center Series

9:00AM-11:00AM: Abstract Number: 1930

Blue Digit Syndrome as the Initial Presentation of Various Diseases: A Case Series

9:00AM-11:00AM: Abstract Number: 1944

Characterization of Interstitial Pneumonia with Autoimmune Features (IPAF) in a National Referral Centre

9:00AM-11:00AM: Abstract Number: 1916

Clinical Features of the Patients with NLRP1 Gene Variants and a Systemic Autoinflammatory Phenotype

9:00AM-11:00AM: Abstract Number: 1921

Clinical Spectrum of VEXAS Syndrome in a Rheumatology Department

9:00AM-11:00AM: Abstract Number: 1938

Cranial Nerve Manifestations in Sarcoidosis Associated with Lymphoma, Non-facial Paralysis, and Other Neurologic Disorders

9:00AM-11:00AM: Abstract Number: 1937

Efficacy of Different Treatment Approaches for Cardiac Sarcoidosis

9:00AM-11:00AM: Abstract Number: 1936

Higher Rates of Disease Control During the Coronavirus Pandemic in Pediatric Patients with Autoinflammatory Periodic Diseases on Canakinumab Treatment – Interim Data from the RELIANCE Registry

9:00AM-11:00AM: Abstract Number: 1941

Identification of VEXAS Syndrome in Mexican Patients with Inflammatory and Hematologic Manifestations

9:00AM-11:00AM: Abstract Number: 1943

IgG4-related Disease: 2010-2022 Case Review and Comparative Evaluation of Diagnostic Criteria

9:00AM-11:00AM: Abstract Number: 1924

Impact of the COVID-19 Pandemic on Clinical and Psychosocial Features of Patients with UCTD

9:00AM-11:00AM: Abstract Number: 1925

Importance of the Patient Pain Experience in Disease Activity Assessment in the Adult SAPHO and Chronic Nonbacterial Osteomyelitis Study

9:00AM-11:00AM: Abstract Number: 1914

Intravenous Immunoglobulins in the Treatment of Idiopathic Inflammatory Myopathies in a Region of Northern Spain: Analysis by Subtypes

9:00AM-11:00AM: Abstract Number: 1927

Manifestations, Management and Outcomes of Interstitial Lung Disease Associated with Anti-synthetase Syndrome: A Systematic Literature Review

9:00AM-11:00AM: Abstract Number: 1918

Nationwide Analysis of Predictors of Sarcoid Inpatient Mortality

9:00AM-11:00AM: Abstract Number: 1913

Neurosarcoidosis Disease Epidemiology. University Hospital in Northern Spain 1999-2019

9:00AM-11:00AM: Abstract Number: 1934

Pooled Safety Analysis from the VOLTAIRE Trials in Patients with Rheumatoid Arthritis, Crohn’s Disease, and Chronic Plaque Psoriasis

9:00AM-11:00AM: Abstract Number: 1935

Pre-exposure Prophylaxis with Tixegvimab/cilgavimab Is Effective in Limiting the Risk and Severity of COVID-19 in Patients with Auto Immune or Inflammatory Diseases at Increased Risk of Severe COVID-19

9:00AM-11:00AM: Abstract Number: 1923

Prevalence and Patterns of Comorbidities in Different Rheumatic Diseases: A Study from Tertiary Healthcare Centre

9:00AM-11:00AM: Abstract Number: 1942

Prevalence and Screening Strategy for Latent Tuberculosis Infection in Patients with Rheumatic Immune-Mediated Diseases

9:00AM-11:00AM: Abstract Number: 1917

Reducing Inadvertent Antifilarial Antibody Testing at an Academic Medical Center: A Quality Improvement Project

9:00AM-11:00AM: Abstract Number: 1928

Response to Sars-Cov2 Vaccination in Rheumatic and Neurological Patients Treated with Different Immunosuppressive Therapies

9:00AM-11:00AM: Abstract Number: 1915

Scleritis and Development of Autoimmune Disease: A Case Series

9:00AM-11:00AM: Abstract Number: 1939

Sinonasal Sarcoidosis Associated with Chronic Pulmonary Disease, Deficiency Anemias, and Obesity

9:00AM-11:00AM: Abstract Number: 1932

The Association Between Initial Ferritin and Complications from Adults Onset Stills Disease and Intensive Care Unit Admission

9:00AM-11:00AM: Abstract Number: 1926

Use of 18F-FDG PET in Assessing Response to Treatment in Adults with Pulmonary Sarcoidosis: A Systematic Literature Review

9:00AM-11:00AM: Abstract Number: 1922

Use of Plasma with High Titer Neutralizing Autoantibodies to Type I Interferons in Patients with Severe Refractory Flare-up of Hidradenitis Suppurativa as Novel Passive Immunotherapy Approach: Trial Protocol

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].